VMIC Adopts Lonza’s Paperless Quality Control Microbiology Platform

Article

The Vaccines Manufacturing and Innovation Centre (VMIC) has chosen Lonza’s MODA-EM solution for the digitalization of its microbiology quality control operations.

The Vaccines Manufacturing and Innovation Centre (VMIC), based in Oxfordshire in the United Kingdom (UK), has chosen Lonza’s MODA-EM solution for the digitalization of its microbiology quality control operations.

According to a Dec 7, 2020 press release, VMIC plans to implement Lonza’s paperless solution in its new manufacturing center, which will be opened in 2021, for automation of quality control. The MODA-EM solution will enable paperless management of microbiological data and, through its electronic approach, reinforces data integrity compliance, enables real-time access to data, and provides fast input necessary to make informed decisions.

“We're proud that VMIC has made the decision to adopt Lonza's MODA-EM Quality Control Microbiology Platform,” said Dr. Orla Cloak, global director of Testing Solutions and Informatics, Lonza, in the press release. “This project comes at a critical time when vaccine developers and manufacturers are scaling up to meet vital global health needs. We look forward to working with VMIC to enable vaccine producers with best practices and the highest levels of data integrity in paperless manufacturing and quality as they serve an important role in the future of public health.”

“A new facility like VMIC faces the challenge of implementing a successful contamination control strategy built on meaningful data analysis,” added Birgit Hartnell, head of Quality Control, VMIC, in the press release. “Add to this the urgent need to be operationally ready in a very short timeframe in order to have the ability to manufacture a vaccine for COVID-19, and you need a system that can be integrated quickly and still delivers the highest standard of compliance. Lonza was able to demonstrate they could deliver this through a rigorous tendering process, and I look forward to working with them.”

Source: Lonza

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy